PYPD 3.59 PolyPid Ltd.
| Range: | 2.95-9.2 | Vol Avg: | 5512 | Last Div: | 0 | Changes: | 0.16 |
| Beta: | 1.32 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 26 2020 | Empoloyees: | 59 | ||
| CUSIP: | M8001Q118 | CIK: | 0001611842 | ISIN: | IL0011326795 | Country: | IL |
| CEO: | Ms. Dikla Czaczkes Akselbrad | Website: | https://www.polypid.com | ||||
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow